Literature DB >> 20222328

Decoding pathogenesis of slow-channel congenital myasthenic syndromes using recombinant expression and mice models.

José David Otero-Cruz1, Carlos Alberto Báez-Pagán, Luisamari Dorna-Pérez, Gary Emanuel Grajales-Reyes, Rosaura Teresa Ramírez-Ordoñez, Carlos A Luciano, Christopher Manuel Gómez, José Antonio Lasalde-Dominicci.   

Abstract

Despite the fact that they are orphan diseases, congenital myasthenic syndromes (CMS) challenge those who suffer from it by causing fatigable muscle weakness, in the most benign cases, to a progressive wasting of muscles that may sentence patients to a wheelchair or even death. Compared to other more common neurological diseases, CMS are rare. Nevertheless, extensive research in CMS is performed in laboratories such as ours. Among the diverse neuromuscular disorders of CMS, we are focusing in the slow-channel congenital myasthenic syndrome (SCS), which is caused by mutations in genes encoding acetylcholine receptor subunits. The study of SCS has evolved from clinical electrophysiological studies to in vitro expression systems and transgenic mice models. The present review evaluates the methodological approaches that are most commonly employed to assess synaptic impairment in SCS and also provides perspectives for new approaches. Electrophysiological methodologies typically employed by physicians to diagnose patients include electromyography, whereas patient muscle samples are used for intracellular recordings, single-channel recordings and toxin binding experiments. In vitro expression systems allow the study of a particular mutation without the need of patient intervention. Indeed, in vitro expression systems have usually been implicated in the development of therapeutic strategies such as quinidine- and fluoxetine-based treatments and, more recently, RNA interference. A breakthrough in the study of SCS has been the development of transgenic mice bearing the mutations that cause SCS. These transgenic mice models have actually been key in the elucidation of the pathogenesis of the SCS mutations by linking IP-3 receptors to calcium overloading, as well as caspases and calpains to the hallmark of SCS, namely endplate myopathy. Finally, we summarize our experiences with suspected SCS patients from a local perspective and comment on one aspect of the contribution of our group in the study of SCS.

Entities:  

Mesh:

Year:  2010        PMID: 20222328      PMCID: PMC2929179     

Source DB:  PubMed          Journal:  P R Health Sci J        ISSN: 0738-0658            Impact factor:   0.705


  69 in total

1.  Macroscopic properties of spontaneous mutations in slow-channel syndrome: correlation by domain and disease severity.

Authors:  Roberto Zayas; Jose Lasalde-Dominicci; Christopher M Gomez
Journal:  Synapse       Date:  2006-11       Impact factor: 2.562

2.  Inositol-1,4,5-triphosphate receptors mediate activity-induced synaptic Ca2+ signals in muscle fibers and Ca2+ overload in slow-channel syndrome.

Authors:  Roberto Zayas; Jason S Groshong; Christopher M Gomez
Journal:  Cell Calcium       Date:  2006-09-12       Impact factor: 6.817

3.  Long-term improvement of slow-channel congenital myasthenic syndrome with fluoxetine.

Authors:  J Colomer; J S Müller; A Vernet; A Nascimento; M Pons; V Gonzalez; A Abicht; H Lochmüller
Journal:  Neuromuscul Disord       Date:  2006-04-18       Impact factor: 4.296

4.  Calpain activation impairs neuromuscular transmission in a mouse model of the slow-channel myasthenic syndrome.

Authors:  Jason S Groshong; Melissa J Spencer; Bula J Bhattacharyya; Elena Kudryashova; Bhupinder P S Vohra; Roberto Zayas; Robert L Wollmann; Richard J Miller; Christopher M Gomez
Journal:  J Clin Invest       Date:  2007-10       Impact factor: 14.808

Review 5.  Congenital myasthenic syndromes.

Authors:  Andrew G Engel
Journal:  Handb Clin Neurol       Date:  2008

6.  Activation of apoptotic pathways at muscle fiber synapses is circumscribed and reversible in a slow-channel syndrome model.

Authors:  Bhupinder P S Vohra; Jason S Groshong; Roberto Zayas; Robert L Wollmann; Christopher M Gomez
Journal:  Neurobiol Dis       Date:  2006-07-11       Impact factor: 5.996

7.  Slow-channel mutation in acetylcholine receptor alphaM4 domain and its efficient knockdown.

Authors:  Xin-Ming Shen; Feza Deymeer; Steven M Sine; Andrew G Engel
Journal:  Ann Neurol       Date:  2006-07       Impact factor: 10.422

8.  Discordant phenotype of two overlapping deletions involving the PAX3 gene in chromosome 2q35.

Authors:  N G Pasteris; B J Trask; S Sheldon; J L Gorski
Journal:  Hum Mol Genet       Date:  1993-07       Impact factor: 6.150

Review 9.  The therapy of congenital myasthenic syndromes.

Authors:  Andrew G Engel
Journal:  Neurotherapeutics       Date:  2007-04       Impact factor: 7.620

10.  Novel beta subunit mutation causes a slow-channel syndrome by enhancing activation and decreasing the rate of agonist dissociation.

Authors:  Manuel F Navedo; José A Lasalde-Dominicci; Carlos A Báez-Pagán; Luzed Díaz-Pérez; Legier V Rojas; Ricardo A Maselli; Julie Staub; Kelly Schott; Roberto Zayas; Christopher M Gomez
Journal:  Mol Cell Neurosci       Date:  2006-04-19       Impact factor: 4.314

View more
  3 in total

1.  Transgenic mouse model reveals an unsuspected role of the acetylcholine receptor in statin-induced neuromuscular adverse drug reactions.

Authors:  G E Grajales-Reyes; C A Báez-Pagán; H Zhu; J G Grajales-Reyes; M Delgado-Vélez; W F García-Beltrán; C A Luciano; O Quesada; R Ramírez; C M Gómez; J A Lasalde-Dominicci
Journal:  Pharmacogenomics J       Date:  2012-06-12       Impact factor: 3.550

2.  Makaluvamine G from the Marine Sponge Zyzzia fuliginosa Inhibits Muscle nAChR by Binding at the Orthosteric and Allosteric Sites.

Authors:  Denis S Kudryavtsev; Ekaterina N Spirova; Irina V Shelukhina; Lina V Son; Yana V Makarova; Natalia K Utkina; Igor E Kasheverov; Victor I Tsetlin
Journal:  Mar Drugs       Date:  2018-03-28       Impact factor: 5.118

3.  Point Mutations of Nicotinic Receptor α1 Subunit Reveal New Molecular Features of G153S Slow-Channel Myasthenia.

Authors:  Denis Kudryavtsev; Anastasia Isaeva; Daria Barkova; Ekaterina Spirova; Renata Mukhutdinova; Igor Kasheverov; Victor Tsetlin
Journal:  Molecules       Date:  2021-02-26       Impact factor: 4.411

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.